Tag: Response Genetics

  • NASDAQ Most Volatile: Horizon Pharma (NASDAQ:HZNP), Response Genetics (NASDAQ:RGDX), Catalyst Pharmaceutical Partners (NASDAQ:CPRX), ACADIA Pharmaceuticals (NASDAQ:ACAD)

    Horizon Pharma (NASDAQ:HZNP) had its price objective reduced by JMP Securities from $22.00 to $21.00 in a report released on Friday,Analyst Ratings.Net reports. JMP Securities currently has an outperform rating on the stock. Horizon Pharma Inc (NASDAQ:HZNP) shares after opening at $16.31 moved to $16.41 on last trade day and at the end of the day closed at $14.85. Company price to sales ratio in past twelve months was calculated as 18.49 and price to cash ratio as 17.13. Horizon Pharma Inc (NASDAQ:HZNP) showed a negative weekly performance of -1.53%.

    Response Genetics (NASDAQ:RGDX) rose 19.99% to $1.44 after the company reported that it has signed contracts with six new provider networks. Response Genetics, Inc. (NASDAQ:RGDX) shares advanced 18.33% in last trading session and ended the day on $1.42. RGDX return on equity ratio is recorded as -200.00% and its return on assets is -39.00%. Response Genetics, Inc. (NASDAQ:RGDX) yearly performance is 10.94%.

    Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX)’s shares gained 6.79% to $2.36. The company on Apr. 3 announced the pricing of its previously announced underwritten public offering of 11,325,000 shares of its common stock at an offering price of $2.21 per share. Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) shares moved up 8.60% in last trading session and was closed at $ 2.40 while trading in range of $2.27 – $2.51 – Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) year to date (YTD) performance is 23.08%.

    ACADIA Pharmaceuticals (NASDAQ:ACAD) has received a consensus rating of “Buy” from the nine ratings firms that are presently covering the stock, Analyst Ratings Net reports. Three research analysts have rated the stock with a hold recommendation and five have issued a buy recommendation on the company. ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) weekly performance is 0.22%. On last trading day company shares ended up $23.06. ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) distance from 50-day simple moving average (SMA50) is -9.80%. Analysts mean target price for the company is $30.43.